If you have been reading about receptor agonist and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-27. Numbers and descriptions here follow the published literature rather than marketing material.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form |
| Solubility | Water and aqueous buffers | Near neutral pH |
| Storage temperature | Minus 20 to minus 80 C | Long-term, lyophilized |
| Analytical method | RP-HPLC | Purity assessment |
| Typical purity | Greater than 95 percent | Research-grade material |
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
Cardiac amyloidosis is a subcategory of amyloidosis where there is depositing of the protein amyloid in the heart muscle and sometimes other organs or structures. Amyloid, a misfolded and insoluble protein, can become a deposit in the heart's atria, valves, or ventricles. These deposits can cause thickening of different sections of the heart, leading to decreased cardiac function and heart failure. The overall decrease in cardiac function leads to a plethora of symptoms. This multisystem disease was often misdiagnosed, with a definitive diagnosis only during autopsy. Advancements of technologies have led to earlier and more accurate diagnosis. However diagnosis may still be delayed as the disease may remain asymptomatic for years as amyloid deposits in the heart and other organs or tissues. Diagnosis may be delayed further as the disease may be misdiagnosed or confused for other more common conditions that cause heart enlargement (such as hypertension or other forms of heart failure). Cardiac amyloidosis has multiple sub-types including light chain, hereditary transthyretin amyloidosis (due to genetic variants leading to misfolded transthyretin protein depositing in the heart and other tissues), and wild type transthyretin amyloidosis (where misfolded transthyretin builds up in heart muscle and other tissues, but with an absence of any mutations).
== History == Nemonapride was developed by scientists at Yamanouchi Pharmaceuticals via structural modification of the benzamide antiemetic and gastroprokinetic agent metoclopramide. It was first described in the scientific literature by 1980. The name nemonapride was first used by 1989 and this name was designated as its INNTooltip International Nonproprietary Name in 1991. The drug was launched in May 1991. However, other sources state that it was launched in 1997.
In 1999, American scientists at the University of California, Berkeley, announced that they had succeeded in synthesizing three atoms of 293Og. These parent nuclei were reported to have successively emitted three alpha particles to form copernicium-281 nuclei, which were claimed to have undergone alpha decay, emitting alpha particles with decay energy 10.68 MeV and half-life 0.90 ms, but their claim was retracted in 2001 as it had been based on data fabricated by Ninov. This isotope was truly produced in 2010 by the same team; the new data contradicted the previous fabricated data. The missing isotopes 278Cn and 279Cn are too heavy to be produced by cold fusion and too light to be produced by hot fusion. They might be filled from above by decay of heavier elements produced by hot fusion, and indeed 280Cn and 281Cn were produced this way. The isotopes 286Cn and 287Cn could be produced by charged-particle evaporation, in the reaction 244Pu(48Ca,αxn) with x equalling 1 or 2.
Sources: en.wikipedia.org
However, the Smith government still professed loyalty to Elizabeth II, and accordingly the document reconstituted Rhodesia as a Commonwealth realm with Elizabeth as "Queen of Rhodesia". The new constitution created the concept of allegiance to the "Constitution of Rhodesia", and introduced the post of Officer Administering the Government, a viceregal figure empowered to sign passed legislation into law on behalf of the monarch if she did not appoint a Governor-General. The Rhodesian Cabinet waited in vain for Wilson's reply for the rest of 9 November and the next day. After briefly meeting Smith late on 10 November, Johnston warned Wilson that evening that the Rhodesians seemed poised to declare independence in the morning. The British prime minister tried repeatedly to call Smith, but did not get through until Smith was already chairing a Cabinet meeting on the independence issue around 08:00 Central Africa Time (06:00 in London) on 11 November. Wilson attempted to talk Smith out of unilateral action by telling him the status quo could continue, and the two argued inconclusively about the proposed Royal Commission. Returning to his Cabinet meeting, Smith reported the conversation to his ministers, and, after debating for a while, the Cabinet came to the conclusion that Wilson was simply attempting to buy more time and that there was no sign of actual progress. Smith asked if Rhodesia should declare its independence, and had each Cabinet minister answer in turn.
"Classical" brown fat is found in highly vascularized deposits in somewhat consistent anatomical locations, such as between the shoulder blades, surrounding the kidneys, the neck, and supraclavicular area, and along the spinal cord. This is the smaller of the two types and has numerous small lipid droplets. Beige fat is the adrenergically inducible cell type that is dispersed throughout adipose tissue. It has greater variability in lipid droplet size and a greater proportion of mitochondria to lipid droplets than white fat, giving it a light brown appearance. In mouse and human organoid models, EPAC1 (exchange proteins directly activated by cAMP) was reported to preferentially increase the production of beige fat relative to WAT.
Like most brainstem tumors, diagnosing diffuse intrinsic pontine glioma usually involves non-invasive brain imaging like MRI, in addition to neurologic physical exam. Biopsies and other surgical procedures are also used when possible. Similar to DIPG, diffuse midline gliomas (DMG) often fall into similar categories for both diagnosis and treatment as DIPG and are often categorized together. More recently, biopsies are performed so that the best option for clinical trials can be chosen. In studies resulting from the DIPG/DMG Registry and in connection with the DIPG/DMG Collaborative, statistics reveal that approximately 150–300 patients are diagnosed with DIPG in the USA per year, the median age of patients with DIPG is approximately 6–7 years old, and the male/female ratio of DIPG patients is 1:1.
Inoculation and fermentation: Skimmed milk is pumped into enclosed vats and heated to approximately 30–32 °C (86–90 °F). A mesophilic starter culture of lactic acid-producing strains (such as Lactococcus lactis ssp. lactis or L. lactis ssp. cremoris) is introduced. These bacteria ferment the milk's lactose into lactic acid, dropping the pH over 4 to 8 hours. Coagulation: A precise dose of microbial or animal rennet is added to facilitate protein cross-linking. The rising acidity and the rennet cause the milk to curdle into a uniform, gelatinous mass. Cutting and cooking: Internal wire grids slice the gel into uniform cubes, determining whether the batch is classified as "small-curd" (<4 mm) or "large-curd" (>8 mm). The vats are heated to 49–54 °C (120–130 °F) under gentle agitation, causing the curd to contract and expel liquid whey. Washing and dressing: The whey is drained, and the curd mass is flooded with chilled, purified water. This stops further bacterial acidification and rinses away excess lactic acid, resulting in a mild flavour profile. The dry curds are then mechanically blended with a pasteurised cream dressing and salt.
Sources: en.wikipedia.org
From 1975 to 1980, the Rhodesian government made several attempts to weaponise chemical and biological agents. Members of the security forces contaminated supplies before replacing them in guerrilla caches or planted them in rural stores to be stolen by the guerrillas during raids. They also poisoned water sources along known infiltration routes along the Rhodesian border, forcing their opponents to travel through more arid regions or carry more water during their treks. The chemical agents most used in the Rhodesian chemical and biological warfare (CBW) programme were parathion (an organophosphate insecticide) and thallium (a heavy metal commonly found in rodenticide). The weapons the Rhodesians selected for use also included Vibrio cholerae (causative agent of cholera) and possibly Bacillus anthracis (causative agent of anthrax). They also looked at using Rickettsia prowazekii (causative agent of epidemic typhus), and Salmonella typhi (causative agent of typhoid fever), and toxins such as ricin and botulinum toxin. Biological agents, namely Vibrio cholerae, had some impact on the fighting capability of ZANLA. Some former officers of the Rhodesian Security Forces alleged that anthrax was used covertly during the late 1970s, but this has been disputed. Use of anthracis, ricin, or botulinum toxin was favoured during assassination attempts of prominent guerrilla commanders.
==== MeSH D12.776.467.374.400 – growth substances ==== MeSH D12.776.467.374.400.442 – hematopoietic cell growth factors MeSH D12.776.467.374.400.442.240 – colony-stimulating factors MeSH D12.776.467.374.400.442.240.075 – colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.075.350 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.075.350.275 – filgrastim MeSH D12.776.467.374.400.442.240.075.375 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.150 – erythropoietin MeSH D12.776.467.374.400.442.240.150.250 – erythropoietin, recombinant MeSH D12.776.467.374.400.442.240.150.250.250 – epoetin alfa MeSH D12.776.467.374.400.442.240.350 – granulocyte colony-stimulating factor MeSH D12.776.467.374.400.442.240.350.375 – granulocyte colony stimulating factor, recombinant MeSH D12.776.467.374.400.442.240.350.375.275 – filgrastim MeSH D12.776.467.374.400.442.240.375 – granulocyte-macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.375.275 – granulocyte macrophage colony-stimulating factors, recombinant MeSH D12.776.467.374.400.442.240.400 – interleukin-3 MeSH D12.776.467.374.400.442.240.500 – macrophage colony-stimulating factor MeSH D12.776.467.374.400.442.240.750 – thrombopoietin MeSH D12.776.467.374.400.442.800 – stem cell factor MeSH D12.776.467.374.400.505 – interleukins MeSH D12.776.467.374.400.505.501 – interleukin-1 MeSH D12.776.467.374.400.505.502 – interleukin-2 MeSH D12.776.467.374.400.505.503 – interleukin-3 MeSH D12.776.467.374.400.505.504 – interleukin-4 MeSH D12.776.467.374.400.505.505 – interleukin-5 MeSH D12.776.467.374.400.505.506 – interleukin-6 MeSH D12.776.467.374.400.505.507 – interleukin-7 MeSH D12.776.467.374.400.505.508 – interleukin-8 MeSH D12.776.467.374.400.505.509 – interleukin-9 MeSH D12.776.467.374.400.505.510 – interleukin-10 MeSH D12.776.467.374.400.505.511 – interleukin-11 MeSH D12.776.467.374.400.505.512 – interleukin-12 MeSH D12.776.467.374.400.505.513 – interleukin-13 MeSH D12.776.467.374.400.505.514 – interleukin-14 MeSH D12.776.467.374.400.505.515 – interleukin-15 MeSH D12.776.467.374.400.505.516 – interleukin-16 MeSH D12.776.467.374.400.505.517 – interleukin-17 MeSH D12.776.467.374.400.505.518 – interleukin-18 MeSH D12.776.467.374.400.800 – transforming growth factor beta
The fentanyl supply chain in Mexico consists of a vast and elusive network, potentially involving hundreds of players. U.S. and Mexican anti-narcotics officials acknowledge that the exact number is unknown. Some brokers operate as specialists within major cartels, while others act independently. A major challenge in disrupting this trade lies in the global chemical industry. Many of the compounds used to manufacture fentanyl have legitimate industrial applications, classifying them as dual-use chemicals. These substances are often unregulated or only lightly controlled in key countries such as the United States, Mexico, and China. This regulatory gap enables brokers to evade detection, navigating between the legal chemical trade and the illicit drug market to acquire the necessary precursors. Several large quantities of illicitly produced fentanyl have been seized by U.S. law enforcement agencies. In November 2016, the DEA uncovered an operation making counterfeit oxycodone and Xanax from a home in Cottonwood Heights, Utah. They found about 70,000 pills in the appearance of oxycodone and more than 25,000 in the appearance of Xanax. The DEA reported that millions of pills could have been distributed from this location over the course of time. The accused owned a tablet press and ordered fentanyl in powder form from China. A seizure of a record amount of fentanyl occurred on 2 February 2019, by U.S. Customs and Border Protection in Nogales, Arizona.
Sources: en.wikipedia.org
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.
Repeated temperature cycling can promote aggregation and peptide degradation. Dividing material into single-use aliquots limits this risk.
Mass spectrometry is commonly used to confirm molecular mass and detect structural modifications. It is often paired with chromatographic purity assessment.
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.